EDITORIALS

Step Change in Safe Harbors: Public–Private Partnerships

Gregory Curt
The Oncologist 2009; 14: 308-310; doi:10.1634/theoncologist.2009-0050
[Full Text] [PDF]  

SUMMARY: This editorial cites SEMATECH, a company formed by collaboration between industry and government in the semiconductor manufacturing field, as an example of how the public and private sectors might begin to work together in the all-important area of biomarkers in cancer drug development.

Facilitating Patient-Centered Cancer Research and a New Era of Drug Discovery

John E. Niederhuber
The Oncologist 2009; 14: 311-312; doi:10.1634/theoncologist.2009-0051
[Full Text] [PDF]  

SUMMARY: This articles highlights the National Cancer Institute's commitment of its resources and expertise to facilitating the development of new translational research.

Four Important Steps Toward 21st Century Care for Patients with Cancer

Mark McClellan, Joshua S. Benner
The Oncologist 2009; 14: 313-316; doi:10.1634/theoncologist.2009-0052
[Full Text] [PDF]  

SUMMARY: This commentary summarizes the discussions that took place at the Conference on Clinical Cancer Research hosted by the Brookings Institution on September 26, 2008.

Vision and Will: The Future of the FDA

David Epstein
The Oncologist 2009; 14: 317-319; doi:10.1634/theoncologist.2009-0053
[Full Text] [PDF]  

SUMMARY: This commentary urges the U.S. Food and Drug Administration to facilitate collaboration among themselves, the industry, and the National Cancer Institute to deliver the best therapies and diagnostics for cancer patients.

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized Medicine

Jeffrey S. Ross, Elzbieta A. Slodkowska, W. Fraser Symmans, Lajos Pusztai, Peter M. Ravdin, Gabriel N. Hortobagyi
The Oncologist 2009; 14: 320-368; doi:10.1634/theoncologist.2008-0230
[Abstract] [Full Text] [PDF]  

SUMMARY: In this review, the discovery and basic biology of the human epidermal growth factor receptor (HER) family of receptors are first considered. The review then considers HER-2 targeted therapies, including trastuzumab-based regimens in the treatment of metastatic breast cancer as well as in the adjuvant and neoadjuvant settings. The review concludes with a consideration of HER-2 status in the prediction of response to non–HER-2 targeted treatments.

Measuring Response with FDG-PET: Methodological Aspects

Martin Allen-Auerbach, Wolfgang A. Weber
The Oncologist 2009; 14: 369-377; doi:10.1634/theoncologist.2008-0119
[Abstract] [Full Text] [PDF]  

SUMMARY: This review provides oncologists with a basic understanding of the practical aspects of using positron emission tomography for treatment monitoring.

Vandetanib (ZD6474), a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) and Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinases: Current Status and Future Directions

Alessandro Morabito, Maria Carmela Piccirillo, Fabiano Falasconi, Gianfranco De Feo, Antonia Del Giudice, Jane Bryce, Massimo Di Maio, Ermelinda De Maio, Nicola Normanno, Francesco Perrone
The Oncologist 2009; 14: 378-390; doi:10.1634/theoncologist.2008-0261
[Abstract] [Full Text] [PDF]  

SUMMARY: This article examines the current preclinical and clinical data concerning the efficacy and safety of vandetanib as a single agent or in combination therapy in the treatment of several tumor types, including non-small cell lung cancer, small cell lung cancer, medullary thyroid cancer, and metastatic breast cancer.

Immunotherapeutics in Development for Prostate Cancer

Andrea L. Harzstark, Eric J. Small
The Oncologist 2009; 14: 391-398; doi:10.1634/theoncologist.2008-0240
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses clinical results for the most promising developments in immunotherapy for the treatment of prostate cancer.

Combined Inhibition of the VEGFR and EGFR Signaling Pathways in the Treatment of NSCLC

Nathan A. Pennell, Thomas J. Lynch, Jr.
The Oncologist 2009; 14: 399-411; doi:10.1634/theoncologist.2008-0276
[Abstract] [Full Text] [PDF]  

SUMMARY: This manuscript focuses on the clinical potential for inhibition of both the vascular endothelial growth factor receptor and the epidermal growth factor receptor signaling pathways in non-small cell lung cancer. The authors describe the rationale and strategies to achieve dual inhibition and summarize key clinical data and ongoing investigations.

The Role of the Taxanes in the Treatment of Older Patients with Advanced Stage Non-Small Cell Lung Cancer

Suresh S. Ramalingam, Fadlo R. Khuri
The Oncologist 2009; 14: 412-424; doi:10.1634/theoncologist.2008-0190
[Abstract] [Full Text] [PDF]  

SUMMARY: This review evaluates the role of taxanes as a treatment option for older patients with advanced non-small cell lung cancer.

Salvage Therapy in Hodgkin's Lymphoma

Jason H. Mendler, Jonathan W. Friedberg
The Oncologist 2009; 14: 425-432; doi:10.1634/theoncologist.2009-0002
[Abstract] [Full Text] [PDF]  

SUMMARY: This review discusses the current evidence behind the treatment of the relapsed/refractory Hodgkin's lymphoma patient and the areas of active investigation in this setting, and details the approach used by the authors at their institution.

Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors

Lucie Lafay-Cousin, Douglas Strother
The Oncologist 2009; 14: 433-444; doi:10.1634/theoncologist.2008-0193
[Abstract] [Full Text] [PDF]  

SUMMARY: This review covers the most recent therapeutic advances for the most common histological subtypes of malignant infant brain tumors: medulloblastoma, supratentorial primitive neuroectodermal tumor, ependymoma, atypical teratoid rhabdoid tumor, choroid plexus carcinoma, and high-grade glioma. Survival and neurocognitive outcome are emphasized.

Commentary: Troublesome Words, Linguistic Precision, and Medical Oncology

Susan E. Bates, Edward J. Benz, Jr.
The Oncologist 2009; 14: 445-447; doi:10.1634/theoncologist.2008-0253
[Full Text] [PDF]  

SUMMARY: This commentary argues for the use of linguistic precision in medical oncology writing and discussions.

Reflections

Monica G. Marcu
The Oncologist 2009; 14: 4000-4003; doi:10.1634/theoncologist.2009-4000
[Full Text] [PDF]  

To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button.